Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Mesenchymal stromal cell (MSC) therapies have been pursued for a broad spectrum of indications but mixed reports on clinical efficacy have given rise to some degree of skepticism regarding the effectiveness of this approach. However, recent reports of successful clinical outcomes and regulatory approvals for graft-versus-host disease, Crohn's disease and critical limb ischemia have prompted a shift in this perspective. With hundreds of clinical trials involving MSCs currently underway and an increasing demand for large-scale manufacturing protocols, there is a critical need to develop standards that can be applied to processing methods and to establish consensus assays for both MSC processing control and MSC product release. Reference materials and validated, uniformly applied tests for quality control of MSC products are needed. Here, we review recent developments in MSC manufacturing technologies, release testing and potency assays. We conclude that, although MSCs hold considerable promise clinically, economies of scale have yet to be achieved although numerous bioreactor technologies for scalable production of MSCs exist. Additionally, rigorous disease-specific product testing and comprehensive understanding of mechanisms of action, which are linked to relevant process and product release potency assays, will be required to ensure that these therapies continue to be successful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, S., Robey, P. G., Riminucci, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.025 · Cited by 2,226
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890
Islam, M. N., Das, S. R., Emin, M. T., Wei, M., Sun, L., Westphalen, K., Rowlands, D. J., Quadri, S. K., Bhattacharya, S., & Bhattacharya, J. (2012) · Nature Medicine · doi:10.1038/nm.2736 · Cited by 1,585
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223
Morrison, T. J., Jackson, M. V., Cunningham, E. K., Kissenpfennig, A., McAuley, D. F., O’Kane, C. M., & Krasnodembskaya, A. D. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0170oc · Cited by 796
Tarte, K., Gaillard, J., Lataillade, J.-J., Fouillard, L., Becker, M., Mossafa, H., Tchirkov, A., Rouard, H., Henry, C., Splingard, M., et al. (2010) · Blood · doi:10.1182/blood-2009-05-219907 · Cited by 430
François, M., Copland, I. B., Yuan, S., Romieu-Mourez, R., Waller, E. K., & Galipeau, J. (2012) · Cytotherapy · doi:10.3109/14653249.2011.623691 · Cited by 375
Zeng, L., Hu, Q., Wang, X., Mansoor, A., Lee, J., Feygin, J., Zhang, G., Suntharalingam, P., Boozer, S., Mhashilkar, A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.659730 · Cited by 260
Cited by
Witwer, K. W., Van Balkom, B. W. M., Bruno, S., Choo, A., Dominici, M., Gimona, M., Hill, A. F., De Kleijn, D., Koh, M., Lai, R. C., et al. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1609206 · Cited by 671
The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review
Česnik, A. B., & Švajger, U. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1400347 · Cited by 128
“Reference materials and validated, uniformly applied tests for quality control of MSC products are required (Robb et al., 2019).”
BackgroundBahsoun, S., Coopman, K., & Akam, E. C. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02054-2 · Cited by 55
“As measured by flow cytometry using 7AAD, the viability in fresh samples was well above the benchmark for clinical application which is ≥ 90% [19] (99.”
MethodSrinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.11.009 · Cited by 44
Hurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products
Childs, P. G., Reid, S., Salmeron-Sanchez, M., & Dalby, M. J. (2020) · Biochemical Journal · doi:10.1042/bcj20190382 · Cited by 27
Metadata
- Authors
- ROBB, K. P., FITZGERALD, J. C., BARRY, F., & VISWANATHAN, S.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 21
- Issue
- 3
- Pages
- 289-306
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W2905083850
- Cited by
- 156
- References
- 13
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. https://app.cochat.ai/papers/10.1016/j.jcyt.2018.10.014
- The paper
- ROBB, K. P., FITZGERALD, J. C., BARRY, F., & VISWANATHAN, S. (2019). Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy. https://doi.org/10.1016/j.jcyt.2018.10.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.